MET/HGF Coexpression as a Novel Predictive Biomarker for Response to MET Inhibitor Therapy in a Case of Psammomatous Melanotic Schwannoma.

Li, Jenny J; Zhang, Xiaoling; Sankar, Neil; Espiritu, Lynn; Redkar, Sanjeev; Yu, Guo-Liang; Kizilbash, Sani H

Li, Jenny J; Zhang, Xiaoling; Sankar, Neil; Espiritu, Lynn; Redkar, Sanjeev; Yu, Guo-Liang; Kizilbash, Sani H.

Afiliação

Li JJ; Division of Medical Oncology, Mayo Clinic, Rochester, MN.
Zhang X; Apollomics Inc, Foster City, CA.
Sankar N; Apollomics Inc, Foster City, CA.
Espiritu L; Apollomics Inc, Foster City, CA.
Redkar S; Apollomics Inc, Foster City, CA.
Yu GL; Apollomics Inc, Foster City, CA.
Kizilbash SH; Division of Medical Oncology, Mayo Clinic, Rochester, MN.

JCO Precis Oncol ; 6: e2200096, 2022 06.

Article em En | MEDLINE | ID: mdl-35675576

Assuntos

Neurilemoma; Biomarcadores; Fator de Crescimento de Hepatócito; Humanos; Neurilemoma/tratamento farmacológico

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neurilemoma Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google